Article Text

Download PDFPDF
Should vericiguat be initiated in geriatric inpatients with heart failure with reduced ejection fraction and a worsening heart failure event prior to discharge?
  1. Julie Hias1,2,
  2. Laura Hellemans1,2,
  3. Karolien Walgraeve1,
  4. Jos Tournoy3,4,
  5. Christophe Vandenbriele5,6,
  6. Lucas Van Aelst5,6,
  7. Lorenz Roger Van der Linden1,2
  1. 1Hospital Pharmacy, UZ Leuven, Leuven, Flemish Brabant, Belgium
  2. 2Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Flemish Brabant, Belgium
  3. 3Department of Geriatric Medicine, UZ Leuven, Leuven, Flemish Brabant, Belgium
  4. 4Department of Public Health and Primary Care, KU Leuven, Leuven, Flanders, Belgium
  5. 5Department of Cardiovascular Sciences, KU Leuven, Leuven, Flemish Brabant, Belgium
  6. 6Department of Cardiology, UZ Leuven, Leuven, Flemish Brabant, Belgium
  1. Correspondence to Dr Lorenz Roger Van der Linden, Hospital Pharmacy, UZ Leuven Campus Gasthuisberg Hospital Pharmacy, 3000 Leuven, Flanders, Belgium; lorenz.vanderlinden{at}


Heart failure (HF) occurs predominantly in older adults. HF patients have an increased risk for an acute exacerbation, which commonly requires hospitalisation. Such a worsening HF (WHF) event has an impact on prognosis. Vericiguat is a novel agent which has been shown to reduce the HF hospitalisation risk in patients with a recent WHF event. It is not fully clear how to position this novel agent in geriatric HF inpatients.

  • Heart failure
  • Practice Guideline

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.